Drugs / FAP immunosuppressive CAR-DC
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07516288 | May 2026 → Dec 2027 expected | dilated cardiomyopathy, heart failure | Second Affiliated Hospital, School of Medicine, Zhejiang University | Recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06902896 | Apr 2025 → Jun 2028 expected | dilated cardiomyopathy, heart failure | Second Affiliated Hospital, School of Medicine, Zhejiang University | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FAP immunosuppressive CAR-DC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07516288 ↗ |
| Known as | iCDC | “FAP-targeted immunosuppressive chimeric antigen receptor-dendritic cell (iCDC) therapy” NCT06902896 ↗ |
| Modality | Cell therapy | “chimeric antigen receptor-dendritic cell (iCDC) therapy” NCT06902896 ↗ |
| Route | Intravenous | “by intravenous infusion” NCT06902896 ↗ |
| Target | FAP | “FAP-targeted immunosuppressive chimeric antigen receptor-dendritic cell (iCDC) therapy” NCT06902896 ↗ |